CDC advisory panel backs use of dengue vaccine in high-risk areas, despite delivery challenges
An expert panel voted Thursday to advise that the Centers for Disease Control and Prevention recommend use of a controversial dengue vaccine, despite the fact that it can only be given to a small fraction of American children and requires a pre-vaccination test in order to be used safely.
The 14 – 0 vote by the Advisory Committee on Immunization Practices clears the way for rollout of Sanofi’s three-dose Dengvaxia vaccine, assuming the CDC accepts the advice. The CDC very rarely overrides recommendations from the group, known as ACIP.
